TrialTrials2023

Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial.

Maryam Hafizi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.